Plasma samples were collected at the inlet and outlet of the column when 1L plasma was treated.

*AChR: Acetylcholine receptor
Shibuya et al. [Article in Japanese] Chiryo 66 : 49-55, 1984

Blood samples for removal rate were collected before and after treatment.
Treated plasma volume: 2L

Shibuya et al. Current Practice in Therapeutic Plasmapheresis 166-172, 1985

Mean values of myasthenia gravis score and titer of AChR antibodies in the 11 improved patients after immunoadsorption therapy. Consecutive immunoadsorption treatments induced a significant fall of the myasthenia gravis score and a decrease in the titer of AChR antibodies. The myasthenia gravis score remained low even on day 42 despite the rise in AChR antibody titers.

Shibuya et al. J Neurol Neurosurg Psychiatry 57: 578-581, 1994

Sixty-three Guillain-Barré Syndrome (GBS) patients were enrolled. These patients were treated with plasma adsorption (PA, n=39: Immusorba TR-350), plasma exchange (PE, n=14), or immunoglobulin treatment (IVIg, n=10). The number of days required for one or two functional grades improvement was 20.3 ±15.3 or 34.8 ± 20.5 days, respectively. Treatment methods (PA, PE, or IVIg) did not significantly influence the outcome. Since PA does not result in a risk of unknown infection, choosing a PA may be justified.

Seta et al. Factors influencing outcome in Guillain-Barré Syndrome: comparison of plasma adsorption against other treatments. Clin Neurol Neurosurg. 107(6): 491-496, 2005

Immunoadsorption Column

Particle Removal Filter

For patients undergoing treatment with angiotensin-converting enzyme (ACE) inhibitor, there is a possibility that treatment with the IMMUSORBA TR-350 will lead to a drop in blood pressure. Simultaneous treatment with ACE inhibitor and the IMMUSORBA TR-350 must be avoided.
The IMMUSORBA TR-350 is intended for the treatment of plasma. Never run whole blood through the IMMUSORBA TR-350. Thrombocytes cannot pass through the IMMUSORBA TR-350 and may cause blockage.
Do not use IMMUSORBA TR-350 with plasma containing a large amount of thrombocytes.

Hirata et al.

IMMUSORBA TR and PH.

Ther Apher Dial. 7:85-90, 2003.

Yoshida et al.

IMMUSORBA TR and IMMUSORBA PH: Basics of design and features of functions.

Ther Apher. 4:127-34, 2000.

Yoshida et al.

IMMUSORBA TR and IMMUSORBA PH: Basics of design and features of functions.

Ther Apher. 4:127-34, 2000.

Haupt et al.

Apheresis and selective adsorption plus immunoglobulin treatment in Guillain-Barré syndrome.

Ther Apher. 4:198-200, 2000.

Ota et al.

Neutrophil activation in immunoadsorption.

Ther Apher. 4:229-34, 2000.

Yang et al.

Plasma adsorption in critical care.

Ther Apher. 6:184-8, 2002.

Hirata et al.

IMMUSORBA TR and PH.

Ther Apher Dial. 7:85-90, 2003.

Beige et al.

Immunoadsorption with tryptophan adsorbers for successful treatment of late steroid-refractory recurrent focal glomerulosclerosis.

Am J Transplant. 3:1459, 2003.

Splendiani et al.

Plasmaperfusion on triptophan columns can improve the clinical outcome of patients affected with myasthenia gravis.

Artif Cells Blood Substit Immobil Biotechnol. 31:69-79, 2003.

Luftl et al.

Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber.

Br J Dermatol. 149:598-605, 2003.

Okamiya et al.

Tryptophan-immobilized column-based immunoadsorption as the choice method for plasmapheresis in Guillain-Barre syndrome.

Ther Apher Dial. 8:248-53, 2004.

Seta et al.

Factors influencing outcome in Guillain-Barré Syndrome: comparison of plasma adsorption against other treatments.

Clin Neurol Neurosurg. 107:491-6, 2005.

Arakawa et al.

Immunoadsorption therapy for a child with Guillain-Barré syndrome subsequent to Mycoplasma infection: a case study.

Brain Dev. 27:431-3, 2005.

Wagner et al.

[Long-term treatment of refractory myasthenia gravis with immunoadsorption].

Dtsch Med Wochenschr. 133:2377-82, 2008. German

Wenning et al.

Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.

N Engl J Med. 361:1075-80, 2009.

Galldiks et al.

Immunoadsorption in patients with chronic inflammatory demyelinating polyradiculoneuropathy with unsatisfactory response to first-line treatment.

Eur Neurol. 66:183-9, 2011.

Nagatomo et al.

Specific immunoadsorption therapy using a tryptophan column in patients with refractory heart failure due to dilated cardiomyopathy.

J Clin Apher. 26:1-8, 2011.

Nagane et al.

Early aggressive treatment strategy against myasthenia gravis.

Eur Neurol. 65:16-22, 2011.

Köhler et al.

A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis.

J Clin Apher. 26:347-55, 2011.

Trebst et al.

Immunoadsorption therapy for steroid-unresponsive relapses in patients with multiple sclerosis.

Blood Purif. 33:1-6, 2012.

Koziolek et al.

Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis.

J Neuroinflammation. 26;9:80, 2012.

Koziolek et al.

Immunoadsorption in steroid-refractory multiple sclerosis.

Atheroscler Suppl. 14:175-8, 2013.

Klingel et al.

Neurologic diseases of the central nervous system with pathophysiologically relevant autoantibodies--perspectives for immunoadsorption.

Atheroscler Suppl. 14:161-5, 2013.

Heigl et al.

Immunoadsorption in steroid-refractory multiple sclerosis: clinical experience in 60 patients.

Atheroscler Suppl. 14:167-73, 2013.

Yonee et al.

Association of acute cerebellar ataxia and human papilloma virus vaccination: a case report.

Neuropediatrics. 44:265-7, 2013.